Isofol Medical: Strengthened patent protection - Redeye

Redeye comments on Isofol’s announcement that the European Patent Office (EPO) has issued an “Intention to Grant” for a new product patent covering a stable lyophilized formulation of its lead candidate arfolitixorin. We view this as a meaningful milestone that likely extends patent protection for arfolitixorin into the mid-2040s, thereby strengthening the asset’s exclusivity profile and commercial potential.

Länk till analysen i sin helhet: https://www.redeye.se/research/1138773/isofol-medical-strengthened-patent-protection?utm_source=finwire&utm_medium=RSS